Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2021-03-06
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is learn if adding cabozantinib (also known as
XL184) to hormonal therapy can help to control prostate cancer. The safety of this drug will
also be studied.
Cabozantinib is designed to block certain proteins in your blood that cause cancer cells to
grow. This may cause cancer cells to die.
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Exelixis High Impact Clinical Research Support Program